출혈성/허혈성 뇌졸중 치료 기기 시장 규모, 점유율, 동향 분석 보고서 : 치료별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)
Hemorrhagic & Ischemic Stroke Treatment Devices Market Size, Share & Trends Analysis Report By Treatment (Aneurysm & Hemorrhagic Stroke Interventions, Ischemic Stroke Interventions ), By End Use, By Region, And Segment Forecasts, 2026 - 2033
상품코드
:
1941439
리서치사
:
Grand View Research
발행일
:
2026년 01월
페이지 정보
:
영문 220 Pages
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
샘플 요청 목록에 추가
출혈성/허혈성 뇌졸중 치료 기기 시장 요약
세계의 출혈성/허혈성 뇌졸중 치료 기기 시장 규모는 2025년 38억 달러로 추정되며, 2033년까지 62억 4,000만 달러에 이를 것으로 예측됩니다.
또한 2026-2033년 연평균 성장률(CAGR)은 6.42%로 예상됩니다. 본 시장은 전 세계 뇌졸중 부담 증가, 고령화, 고혈압, 당뇨병 등 위험인자 유병률 증가에 의해 주도되고 있습니다.
저침습적 혈관 내 치료법의 보급 확대와 더불어 기기의 안전성, 정확성, 임상 결과의 개선이 수요를 가속화하고 있습니다. 또한, 종합 뇌졸중 센터의 확충과 신속한 치료 경로의 개발은 첨단 뇌졸중 치료 기술의 폭넓은 활용을 뒷받침하고 있습니다.
출혈성 뇌졸중 발생률 증가에 따라 향후 몇 년 동안 출혈성 뇌졸중 치료 기기에 대한 수요가 크게 증가할 것으로 예측됩니다. 세계뇌졸중기구가 발표한 '세계 뇌졸중 팩트시트 2025'에 따르면, 연간 1,200만 건 이상의 새로운 뇌졸중 사례가 발생하고 있으며, 전 세계 인구의 약 4분의 1이 일생 동안 뇌졸중을 경험할 것으로 예측됩니다. 보고서에 따르면, 전체 뇌졸중 사례 중 뇌내출혈(ICH)이 28.8%, 지주막하출혈(SAH)이 5.8%를 차지해 출혈성 뇌졸중의 부담이 매우 큰 것으로 나타났습니다. 이 질환의 유병률 증가는 예측 기간 동안 시장 성장을 이끄는 주요 요인이 될 것으로 예측됩니다.
조기 저침습적 뇌내출혈(ICH) 제거 및 내시경적 혈종 제거를 포함한 저침습적 치료 전략에 대한 관심이 높아짐에 따라 예측 기간 동안 시장 성장의 주요 동력이 될 것으로 예측됩니다. 또한, 현재 진행 중인 임상시험은 시술의 안전성과 임상 결과를 개선하는 기술 개발을 뒷받침하고 있습니다. 예를 들어, 2024년 4월 니코는 ENRICH(조기 저침습적 뇌내 출혈 제거) 임상시험의 좋은 결과를 보고했습니다. 브레인패스-마이리어드 시스템을 이용한 조기 최소침습적 부수적 수술(MIPS)은 안전하며, 현재 ICH의 표준 치료인 가이드라인에 따른 내과적 치료 단독 치료와 비교해 우수한 치료 성적을 보였습니다.
연구 기관, 학술 센터 및 업계 관계자의 임상시험 증가는 출혈성 뇌졸중 치료 기기 시장의 주요 촉진요인입니다. 이러한 시험은 저침습적 차세대 기술의 안전성과 유효성을 검증하는 임상적 증거를 생성하여 규제 당국의 승인과 임상의의 신뢰를 뒷받침합니다. 또한, 혁신을 촉진하고, 치료 적응증을 확대하며, 첨단 기기의 채택과 상용화를 가속화함으로써 지속적인 시장 성장을 주도하고 있습니다.
신경혈관 기기 기술의 급속한 발전은 시장 확대를 견인하는 데 중요한 역할을 할 것으로 예측됩니다. 업계 관계자들은 시술의 정확성, 안전성, 치료 효과를 향상시킬 수 있는 차세대 솔루션 개발과 상용화에 집중하고 있습니다. 또한, 기기 설계 개선, 재료 개선, 영상 진단과의 호환성 향상과 같은 혁신은 임상의가 복잡한 케이스를 보다 효율적으로 관리할 수 있게 함으로써 시장 성장을 더욱 촉진하고 있습니다.
목차 제1장 조사 방법과 범위
제2장 주요 요약
제3장 출혈성/허혈성 뇌졸중 치료 기기 시장 변수, 동향, 범위
제4장 출혈성/허혈성 뇌졸중 치료 기기 시장 : 치료별 추정 및 동향 분석
제5장 출혈성/허혈성 뇌졸중 치료 기기 시장 : 최종 용도별 추정 및 동향 분석
제6장 출혈성/허혈성 뇌졸중 치료 기기 시장 : 지역별 추정 및 동향 분석
제7장 경쟁 구도
LSH
영문 목차
Hemorrhagic & Ischemic Stroke Treatment Devices Market Summary
The global hemorrhagic & ischemic stroke treatment devices market size was estimated at USD 3.80 billion in 2025 and is projected to reach USD 6.24 billion by 2033, growing at a CAGR of 6.42% from 2026 to 2033. The market is driven by the rising global burden of stroke, aging populations, and increasing prevalence of risk factors such as hypertension and diabetes.
Growing adoption of minimally invasive endovascular procedures, along with improvements in device safety, precision, and clinical outcomes, is accelerating demand. In addition, the expansion of comprehensive stroke centers and the development of faster treatment pathways are supporting the wider utilization of advanced stroke treatment technologies.
The rising incidence of hemorrhagic strokes is expected to significantly increase demand for hemorrhagic stroke treatment devices over the coming years. According to the Global Stroke Fact Sheet 2025 published by the World Stroke Organization, more than 12 million new stroke cases occur annually, and nearly one in four people worldwide will experience a stroke during their lifetime. The report indicates that intracerebral hemorrhage (ICH) accounts for 28.8% and subarachnoid hemorrhage (SAH) for 5.8% of all incident strokes, underscoring the substantial hemorrhagic stroke burden. The growing prevalence of this disease is anticipated to be a key factor supporting market growth during the forecast period.
The increasing focus on minimally invasive treatment strategies, including early minimally invasive evacuation of intracerebral hemorrhage (ICH) and endoscopic hematoma removal, is expected to be a key driver of market growth over the forecast period. Furthermore, ongoing clinical trials are supporting the development of technologies that improve procedural safety and clinical outcomes. For instance, in April 2024, NICO Corporation reported positive results from the ENRICH (Early MiNimally-invasive Removal of ICH) clinical trial, showing that early minimally invasive parafascicular surgery (MIPS) using its BrainPath and Myriad systems was safe and demonstrated superior outcomes compared with guideline-based medical management alone, the current standard of care for ICH.
The increasing volume of clinical trials conducted by research institutions, academic centers, and industry players is a key driver of the hemorrhagic stroke treatment devices market. These trials generate clinical evidence that validates the safety and effectiveness of minimally invasive and next-generation technologies, supporting regulatory approvals and clinician confidence. In addition, they facilitate innovation, expand treatment indications, and accelerate the adoption and commercialization of advanced devices, thereby driving sustained market growth.
The rapid advancement of neurovascular device technology is expected to play a crucial role in driving market expansion. Industry participants are focusing on developing and commercializing next-generation solutions that improve procedural accuracy, safety, and treatment effectiveness. In addition, innovations such as enhanced device design, improved materials, and better imaging compatibility are helping clinicians manage complex cases more efficiently, further supporting market growth.
Global Hemorrhagic & Ischemic Stroke Treatment Devices Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis on the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global hemorrhagic & ischemic stroke treatment devices market report based on treatment, end use, and region:
Treatment Outlook (Revenue, USD Million, 2021 - 2033)
Aneurysm & Hemorrhagic Stroke Interventions
By Indication
Intracranial Aneurysm
cSDH (MMA Embolization)
AVM & AVF Embolization
By Device
Embolization Coiling Systems
Bare Platinum Coils
Coated / Bioactive Coils
Flow Diversion Systems
Standard Flow-Diverting Stents (e.g., Pipeline)
Next-Generation / Surface-Modified Flow Diverters
Intrasaccular Flow Disruption Devices
Woven EndoBridge (WEB)
Contour Neurovascular System
Luna Aneurysm Embolization System
Liquid Embolization Agents
Non-Adhesive Liquid Embolics (Onyx, Squid, PHIL)
Adhesive Liquid Embolics (NBCA)
Ischemic Stroke Interventions (Mechanical Revascularization)
Stent Retriever Systems
Aspiration-Based Thrombectomy Systems
Cerebral Angioplasty & Vascular Remodeling
Balloon Angioplasty Systems
Intracranial & Carotid Stenting Systems
Coil-Assisted Adjunctive Devices (Balloon-assisted and stent-assisted)
Ancillary & Procedural Access Devices
Guiding & Distal Access Catheters
Microcatheters
Access Sheaths & Wires
End Use Outlook (Revenue, USD Million, 2021 - 2033)
Hospitals
Specialty Neurosurgery Centers
Ambulatory Surgical Centers
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
Europe
Sweden
Denmark
Norway
Germany
UK
France
Italy
Spain
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
Table of Contents Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Treatment
1.1.2. End Use
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR's Internal Database
1.5. Details of primary research
1.5.1. Data for primary interviews in North America
1.5.2. Data for primary interviews in Europe
1.5.3. Data for primary interviews in Asia Pacific
1.5.4. Data for primary interviews in Latin America
1.5.5. Data for Primary interviews in MEA
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.1.1. Approach 1: Commodity flow approach
1.7.2. Volume price analysis (Model 2)
1.7.2.1. Approach 2: Volume price analysis
1.8. Research Scope and Assumptions
1.8.1. List of Secondary Sources
1.8.2. List of Primary Sources
1.8.3. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Hemorrhagic & Ischemic Stroke Treatment Devices Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Drivers Analysis
3.2.1.1. Rising burden of hemorrhagic stroke
3.2.1.2. Growing focus on minimally invasive procedures
3.2.1.3. Technological advancements in neurovascular devices
3.2.2. Market Restraints Analysis
3.2.2.1. High cost of devices and procedures
3.2.2.2. Product recalls
3.2.3. Market Opportunity Analysis
3.2.3.1. Growing emphasis on R&D expansion
3.2.3.2. Rising public awareness about hemorrhagic stroke
3.2.3.3. Increasing clinical trials
3.2.3.4. Increasing launches of devices for ischemic stroke treatment
3.2.3.5. Expansion opportunities in emerging markets
3.2.3.6. Rising stroke incidence among younger adults
3.2.4. Market Challenge Analysis
3.2.4.1. Complications associated with neurovascular treatments
3.2.4.2. Limited skilled professionals
3.3. Hemorrhagic & Ischemic Stroke Treatment Devices Market Analysis Tools
3.3.1. Porter's Analysis
3.3.1.1. Bargaining power of the suppliers
3.3.1.2. Bargaining power of the buyers
3.3.1.3. Threats of substitution
3.3.1.4. Threats from new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic and Social landscape
3.3.2.3. Technological landscape
3.3.2.4. Environmental landscape
3.3.2.5. Legal landscape
Chapter 4. Hemorrhagic & Ischemic Stroke Treatment Devices Market: Treatment Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Global Hemorrhagic & Ischemic Stroke Treatment Devices Market: Treatment Movement Analysis, 2025 & 2033 (USD Million)
4.3. Global Hemorrhagic & Ischemic Stroke Treatment Devices Market Size & Trend Analysis, by Treatment, 2021 to 2033 (USD Million)
4.4. Aneurysm & Hemorrhagic Stroke Interventions
4.4.1. Aneurysm & hemorrhagic stroke interventions market revenue estimates and forecasts, 2021 - 2033 (USD Million)
4.4.2. By indication
4.4.2.1. By indication market revenue estimates and forecasts, 2021 - 2033 (USD Million)
4.4.2.2. Intracranial aneurysm
4.4.2.2.1. Intracranial aneurysm market revenue estimates and forecasts, 2021 - 2033 (USD Million)
4.4.2.3. cSDH (MMA Embolization)
4.4.2.3.1. cSDH (MMA Embolization) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
4.4.2.4. AVM & AVF embolization
4.4.2.4.1. AVM & AVF embolization market revenue estimates and forecasts, 2021 - 2033 (USD Million)
4.4.3. By device
4.4.3.1. By device market revenue estimates and forecasts, 2021 - 2033 (USD Million)
4.4.3.2. Embolization coiling systems
4.4.3.1.1. Embolization coiling systems market revenue estimates and forecasts, 2021 - 2033 (USD Million)
4.4.3.2. Flow diversion systems
4.4.3.2.1. Flow diversion systems market revenue estimates and forecasts, 2021 - 2033 (USD Million)
4.4.3.3. Intrasaccular flow disruption devices
4.4.2.3.1. Intrasaccular flow disruption devices market revenue estimates and forecasts, 2021 - 2033 (USD Million)
4.4.3.4. Liquid embolization agents
4.4.3.4.1. Liquid embolization agents market revenue estimates and forecasts, 2021 - 2033 (USD Million)
4.5. Ischemic Stroke Interventions (Mechanical Revascularization)
4.5.1. Ischemic stroke interventions (Mechanical Revascularization) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
4.5.2. Stent retriever systems
4.5.2.1. Stent retriever systems market revenue estimates and forecasts, 2021 - 2033 (USD Million)
4.5.3. Aspiration-based thrombectomy systems
4.5.3.1. Aspiration-based thrombectomy systems market revenue estimates and forecasts, 2021 - 2033 (USD Million)
4.6. Cerebral Angioplasty & Vascular Remodeling
4.6.1. Cerebral angioplasty & vascular remodeling market revenue estimates and forecasts, 2021 - 2033 (USD Million)
4.6.2. Balloon angioplasty systems
4.6.2.1. Balloon angioplasty systems market revenue estimates and forecasts, 2021 - 2033 (USD Million)
4.6.3. Intracranial & carotid stenting systems
4.6.3.1. Intracranial & carotid stenting systems market revenue estimates and forecasts, 2021 - 2033 (USD Million)
4.6.4. Coil-assisted adjunctive devices (Balloon-assisted and stent-assisted)
4.6.4.1. Coil-assisted adjunctive devices (Balloon-assisted and stent-assisted) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
4.7. Ancillary & procedural access devices
4.7.1. Ancillary & procedural access devices market revenue estimates and forecasts, 2021 - 2033 (USD Million)
4.7.2. Guiding & distal access catheters
4.7.2.1. Guiding & distal access catheters market revenue estimates and forecasts, 2021 - 2033 (USD Million)
4.7.3. Microcatheters
4.7.3.1. Microcatheters market revenue estimates and forecasts, 2021 - 2033 (USD Million)
4.7.4. Access sheaths & wires
4.7.4.1. Access sheaths & wires market revenue estimates and forecasts, 2021 - 2033 (USD Million)
Chapter 5. Hemorrhagic & Ischemic Stroke Treatment Devices Market: End Use Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Global Hemorrhagic & Ischemic Stroke Treatment Devices Market: End use Movement Analysis, 2025 & 2033 (USD Million)
5.3. Global Hemorrhagic & Ischemic Stroke Treatment Devices Market Size & Trend Analysis, by End use 2021 to 2033 (USD Million)
5.4. Hospitals
5.4.1. Hospitals market revenue estimates and forecasts, 2021 - 2033 (USD Million)
5.5. Specialty Neurosurgery Centers
5.5.1. Specialty neurosurgery centers market revenue estimates and forecasts, 2021 - 2033 (USD Million)
5.6. Ambulatory Surgical Centers
5.6.1. Ambulatory surgical centers market revenue estimates and forecasts, 2021 - 2033 (USD Million)
Chapter 6. Hemorrhagic & Ischemic Stroke Treatment Devices Market: Regional Estimates & Trend Analysis by Treatment, and End Use
6.1. Regional Dashboard
6.2. Market Size and Trend Analysis, 2021 to 2033
6.3. North America
6.3.1. North America hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
6.3.2. U.S.
6.3.2.1. Key country dynamics
6.3.2.2. Competitive scenario
6.3.2.3. Regulatory framework
6.3.2.4. Reimbursement scenario
6.3.2.5. U.S. hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
6.3.3. Canada
6.3.3.1. Key country dynamics
6.3.3.2. Competitive scenario
6.3.3.3. Regulatory framework
6.3.3.4. Reimbursement scenario
6.3.3.5. Canada hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
6.3.4. Mexico
6.3.4.1. Key country dynamics
6.3.4.2. Competitive scenario
6.3.4.3. Regulatory framework
6.3.4.4. Reimbursement scenario
6.3.4.5. Mexico hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
6.4. Europe
6.4.1. Europe hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
6.4.2. UK
6.4.2.1. Key country dynamics
6.4.2.2. Competitive scenario
6.4.2.3. Regulatory framework
6.4.2.4. Reimbursement scenario
6.4.2.5. UK hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
6.4.3. Germany
6.4.3.1. Key country dynamics
6.4.3.2. Competitive scenario
6.4.3.3. Regulatory framework
6.4.3.4. Reimbursement scenario
6.4.3.5. Germany hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
6.4.4. France
6.4.4.1. Key country dynamics
6.4.4.2. Competitive scenario
6.4.4.3. Regulatory framework
6.4.4.4. Reimbursement scenario
6.4.4.5. France hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
6.4.5. Italy
6.4.5.1. Key country dynamics
6.4.5.2. Competitive scenario
6.4.5.3. Regulatory framework
6.4.5.4. Reimbursement scenario
6.4.5.5. Italy hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
6.4.6. Spain
6.4.6.1. Key country dynamics
6.4.6.2. Competitive scenario
6.4.6.3. Regulatory framework
6.4.6.4. Reimbursement scenario
6.4.6.5. Spain hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
6.4.7. Sweden
6.4.7.1. Key country dynamics
6.4.7.2. Competitive scenario
6.4.7.3. Regulatory framework
6.4.7.4. Reimbursement scenario
6.4.7.5. Sweden hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
6.4.8. Denmark
6.4.8.1. Key country dynamics
6.4.8.2. Competitive scenario
6.4.8.3. Regulatory framework
6.4.8.4. Reimbursement scenario
6.4.8.5. Denmark hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
6.4.9. Norway
6.4.9.1. Key country dynamics
6.4.9.2. Competitive scenario
6.4.9.3. Regulatory framework
6.4.9.4. Reimbursement scenario
6.4.9.5. Norway hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
6.5. Asia Pacific
6.5.1. Asia Pacific hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
6.5.2. China
6.5.2.1. Key country dynamics
6.5.2.2. Competitive scenario
6.5.2.3. Regulatory framework
6.5.2.4. Reimbursement scenario
6.5.2.5. China hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
6.5.3. Japan
6.5.3.1. Key country dynamics
6.5.3.2. Competitive scenario
6.5.3.3. Regulatory framework
6.5.3.4. Reimbursement scenario
6.5.3.5. Japan hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
6.5.4. India
6.5.4.1. Key country dynamics
6.5.4.2. Competitive scenario
6.5.4.3. Regulatory framework
6.5.4.4. Reimbursement scenario
6.5.4.5. India hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
6.5.5. South Korea
6.5.5.1. Key country dynamics
6.5.5.2. Competitive scenario
6.5.5.3. Regulatory framework
6.5.5.4. Reimbursement scenario
6.5.5.5. South Korea hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
6.5.6. Australia
6.5.6.1. Key country dynamics
6.5.6.2. Competitive scenario
6.5.6.3. Regulatory framework
6.5.6.4. Reimbursement scenario
6.5.6.5. Australia hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
6.5.7. Thailand
6.5.7.1. Key country dynamics
6.5.7.2. Competitive scenario
6.5.7.3. Regulatory framework
6.5.7.4. Reimbursement scenario
6.5.7.5. Thailand hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
6.6. Latin America
6.6.1. Latin America hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
6.6.2. Brazil
6.6.2.1. Key country dynamics
6.6.2.2. Competitive scenario
6.6.2.3. Regulatory framework
6.6.2.4. Reimbursement scenario
6.6.2.5. Brazil hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
6.6.3. Argentina
6.6.3.1. Key country dynamics
6.6.3.2. Competitive scenario
6.6.3.3. Regulatory framework
6.6.3.4. Reimbursement scenario
6.6.3.5. Argentina hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
6.7. Middle East and Africa
6.7.1. Middle East and Africa hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
6.7.2. South Africa
6.7.2.1. Key country dynamics
6.7.2.2. Competitive scenario
6.7.2.3. Regulatory framework
6.7.2.4. Reimbursement scenario
6.7.2.5. South Africa hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
6.7.3. Saudi Arabia
6.7.3.1. Key country dynamics
6.7.3.2. Competitive scenario
6.7.3.3. Regulatory framework
6.7.3.4. Reimbursement scenario
6.7.3.5. Saudi Arabia hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
6.7.4. UAE
6.7.4.1. Key country dynamics
6.7.4.2. Competitive scenario
6.7.4.3. Regulatory framework
6.7.4.4. Reimbursement scenario
6.7.4.5. UAE hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
6.7.5. Kuwait
6.7.5.1. Key country dynamics
6.7.5.2. Competitive scenario
6.7.5.3. Regulatory framework
6.7.5.4. Reimbursement scenario
6.7.5.5. Kuwait hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis by Key Market Participants
7.2. Company Categorization
7.3. Company Market Share Analysis, 2025
7.4. Company Heat Map Analysis
7.5. Strategy Mapping
7.5.1. Expansion
7.5.2. Mergers & Acquisition
7.5.3. Partnerships & Collaborations
7.5.4. New Treatment Launches
7.5.5. Research And Development
7.5.6. Company Profiles
7.5.7. Medtronic
7.5.7.1. Company overview
7.5.7.2. Financial performance
7.5.7.3. Treatment Benchmarking
7.5.7.4. Strategic initiatives
7.5.8. MicroVention, Inc. (Terumo Corporation)
7.5.8.1. Company overview
7.5.8.2. Financial performance
7.5.8.3. Treatment Benchmarking
7.5.8.4. Strategic initiatives
7.5.9. Balt
7.5.9.1. Company overview
7.5.9.2. Financial performance
7.5.9.3. Treatment Benchmarking
7.5.9.4. Strategic initiatives
7.5.10. Scientia Vascular, Inc.
7.5.10.1. Company overview
7.5.10.2. Financial performance
7.5.10.3. Treatment Benchmarking
7.5.10.4. Strategic initiatives
7.5.11. MicroPort Scientific Corporation
7.5.11.1. Company overview
7.5.11.2. Financial performance
7.5.11.3. Treatment Benchmarking
7.5.11.4. Strategic initiatives
7.5.12. Johnson & Johnson (MedTech)
7.5.12.1. Company overview
7.5.12.2. Financial performance
7.5.12.3. Treatment Benchmarking
7.5.12.4. Strategic initiatives
7.5.13. phenox GmbH (Wallaby Medical)
7.5.13.1. Company overview
7.5.13.2. Financial performance
7.5.13.3. Treatment Benchmarking
7.5.13.4. Strategic initiatives
7.5.14. Acandis GmbH
7.5.14.1. Company overview
7.5.14.2. Financial performance
7.5.14.3. Treatment Benchmarking
7.5.14.4. Strategic initiatives
7.5.15. B. Braun SE
7.5.15.1. Company overview
7.5.15.2. Financial performance
7.5.15.3. Treatment Benchmarking
7.5.15.4. Strategic initiatives
7.5.16. Integra LifeSciences
7.5.16.1. Company overview
7.5.16.2. Financial performance
7.5.16.3. Treatment Benchmarking
7.5.16.4. Strategic initiatives
7.5.17. Infinity Neuro LLC
7.5.17.1. Company overview
7.5.17.2. Financial performance
7.5.17.3. Treatment Benchmarking
7.5.17.4. Strategic initiatives
7.5.18. Penumbra, Inc.
7.5.18.1. Company overview
7.5.18.2. Financial performance
7.5.18.3. Treatment Benchmarking
7.5.18.4. Strategic initiatives
7.5.19. Boston Scientific Corporation
7.5.19.1. Company overview
7.5.19.2. Financial performance
7.5.19.3. Treatment Benchmarking
7.5.19.4. Strategic initiatives
7.5.20. Stryker
7.5.20.1. Company overview
7.5.20.2. Financial performance
7.5.20.3. Treatment Benchmarking
7.5.20.4. Strategic initiatives
7.5.21. Peter LAZIC GmbH
7.5.21.1. Company overview
7.5.21.2. Financial performance
7.5.21.3. Treatment Benchmarking
7.5.21.4. Strategic initiatives
7.5.22. Vesalio Inc.
7.5.22.1. Company overview
7.5.22.2. Financial performance
7.5.22.3. Treatment Benchmarking
7.5.22.4. Strategic initiatives
관련자료
